267 related articles for article (PubMed ID: 33042262)
1. Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression.
Lin CC; Huang YK; Cho CF; Lin YS; Lo CC; Kuo TT; Tseng GC; Cheng WC; Chang WC; Hsiao TH; Lai LC; Shih JY; Liu YH; Chao KSC; Hsu JL; Lee PC; Sun X; Hung MC; Sher YP
Theranostics; 2020; 10(24):10925-10939. PubMed ID: 33042262
[No Abstract] [Full Text] [Related]
2. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
[TBL] [Abstract][Full Text] [Related]
3. Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.
Tohmé R; Izadmehr S; Gandhe S; Tabaro G; Vallabhaneni S; Thomas A; Vasireddi N; Dhawan NS; Ma'ayan A; Sharma N; Galsky MD; Ohlmeyer M; Sangodkar J; Narla G
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830869
[TBL] [Abstract][Full Text] [Related]
4. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
Martin P; Stewart E; Pham NA; Mascaux C; Panchal D; Li M; Kim L; Sakashita S; Wang D; Sykes J; Friess T; Shepherd FA; Liu G; Tsao MS
Clin Lung Cancer; 2016 Sep; 17(5):375-383.e2. PubMed ID: 26926157
[TBL] [Abstract][Full Text] [Related]
7. Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis.
Lou Y; Xu J; Zhang Y; Zhang W; Zhang X; Gu P; Zhong H; Wang H; Lu J; Han B
Cell Death Dis; 2021 Feb; 12(2):170. PubMed ID: 33568630
[TBL] [Abstract][Full Text] [Related]
8. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
Lu GS; Li M; Xu CX; Wang D
Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
[TBL] [Abstract][Full Text] [Related]
9. Effects of different brain surveillance strategies on outcomes for patients with EGFR-mutant metastatic lung adenocarcinoma under targeted therapy.
Shen CI; Huang HC; Chiang CL; Luo YH; Shiao TH; Chiu CH
Lung Cancer; 2019 Dec; 138():52-57. PubMed ID: 31634655
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
Yang Z; Zhang SL; Hu X; Tam KY
Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498
[TBL] [Abstract][Full Text] [Related]
11. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
12. TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target.
Yu JJ; Zhou DD; Yang XX; Cui B; Tan FW; Wang J; Li K; Shang S; Zhang C; Lv XX; Zhang XW; Liu SS; Yu JM; Wang F; Huang B; Hua F; Hu ZW
Nat Commun; 2020 Jul; 11(1):3660. PubMed ID: 32694521
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor.
Rong X; Liang Y; Han Q; Zhao Y; Jiang G; Zhang X; Lin X; Liu Y; Zhang Y; Han X; Zhang M; Luo Y; Li P; Wei L; Yan T; Wang E
J Thorac Oncol; 2019 Oct; 14(10):1766-1783. PubMed ID: 31228625
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases.
Ke SB; Qiu H; Chen JM; Shi W; Chen YS
Curr Med Sci; 2018 Dec; 38(6):1062-1068. PubMed ID: 30536070
[TBL] [Abstract][Full Text] [Related]
15. Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties.
Si J; Ma Y; Bi JW; Xiong Y; Lv C; Li S; Wu N; Yang Y
J Exp Clin Cancer Res; 2019 Dec; 38(1):481. PubMed ID: 31801598
[TBL] [Abstract][Full Text] [Related]
16. A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation.
Yang H; He D; Wang F; Deng Q; Xie Z
Clin Exp Metastasis; 2020 Jun; 37(3):391-399. PubMed ID: 32356218
[TBL] [Abstract][Full Text] [Related]
17. PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.
Wu DW; Wu TC; Chen CY; Lee H
Clin Cancer Res; 2016 Nov; 22(21):5370-5382. PubMed ID: 27178741
[TBL] [Abstract][Full Text] [Related]
18. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.
Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH
Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282
[TBL] [Abstract][Full Text] [Related]
19. Small Molecule T315 Promotes Casitas B-Lineage Lymphoma-Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation.
Huang KY; Kao SH; Wang WL; Chen CY; Hsiao TH; Salunke SB; Chen JJ; Su KY; Yang SC; Hong TM; Chen CS; Yang PC
Am J Respir Crit Care Med; 2016 Apr; 193(7):753-66. PubMed ID: 26583948
[TBL] [Abstract][Full Text] [Related]
20. Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors.
Ménard L; Floc'h N; Martin MJ; Cross DAE
Cancer Res; 2018 Jun; 78(12):3267-3279. PubMed ID: 29555874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
